2472 related articles for article (PubMed ID: 35727759)
1. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong.
Li X; Gao L; Tong X; Chan VKY; Chui CSL; Lai FTT; Wong CKH; Wan EYF; Chan EWY; Lau KK; Lau CS; Wong ICK
J Autoimmun; 2022 Jun; 130():102830. PubMed ID: 35461018
[TBL] [Abstract][Full Text] [Related]
3. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
[TBL] [Abstract][Full Text] [Related]
4. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
5. Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
Kang W; Shami JJP; Yan VKC; Ye X; Blais JE; Li X; Lee VHF; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Wong ICK; Chan EW
J Hematol Oncol; 2022 May; 15(1):66. PubMed ID: 35590336
[TBL] [Abstract][Full Text] [Related]
6. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
7. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
[TBL] [Abstract][Full Text] [Related]
8. mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study.
Wan EYF; Chui CSL; Mok AHY; Xu W; Yan VKC; Lai FTT; Li X; Wong CKH; Chan EWY; Lui DTW; Tan KCB; Hung IFN; Lam CLK; Leung GM; Wong ICK
Drug Saf; 2022 Dec; 45(12):1477-1490. PubMed ID: 36184720
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines.
Wong CKH; Mak LY; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng WY; Cheng FWT; Yuen MF; Wong ICK
J Hepatol; 2022 Nov; 77(5):1339-1348. PubMed ID: 35817224
[TBL] [Abstract][Full Text] [Related]
10. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients.
Wong CKH; Lui DTW; Xiong X; Chui CSL; Lai FTT; Li X; Wan EYF; Cheung CL; Lee CH; Woo YC; Au ICH; Chung MSH; Cheng FWT; Tan KCB; Wong ICK
BMC Med; 2022 Oct; 20(1):339. PubMed ID: 36229814
[TBL] [Abstract][Full Text] [Related]
11. Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines.
Cheng FWT; Wong CKH; Qin SX; Chui CSL; Lai FTT; Li X; Wan EYF; Chan EW; Au CH; Ye X; Tang SCW; Wong ICK
Nephrol Dial Transplant; 2023 Jan; 38(1):129-137. PubMed ID: 36367015
[TBL] [Abstract][Full Text] [Related]
12. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
14. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.
Wan EYF; Wang Y; Chui CSL; Mok AHY; Xu W; Yan VKC; Lai FTT; Li X; Wong CKH; Chan EWY; Lau KK; Cowling BJ; Hung IFN; Wong ICK
Lancet Healthy Longev; 2022 Jul; 3(7):e491-e500. PubMed ID: 35813276
[TBL] [Abstract][Full Text] [Related]
15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
16. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study.
Lai FTT; Chua GT; Chan EWW; Huang L; Kwan MYW; Ma T; Qin X; Chui CSL; Li X; Wan EYF; Wong CKH; Chan EWY; Wong ICK; Ip P
Emerg Microbes Infect; 2022 Dec; 11(1):885-893. PubMed ID: 35254219
[TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
19. Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease.
Ye X; Ma T; Blais JE; Yan VKC; Kang W; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Tse HF; Siu CW; Wong ICK; Chan EW
Cardiovasc Res; 2022 Jul; 118(10):2329-2338. PubMed ID: 35732274
[TBL] [Abstract][Full Text] [Related]
20. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
